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Omeprazole (OME) is a proton pump inhibitor (PPI) with 58% bioavailability after single oral dose, presenting large inter-individual variations and significant drug-drug interactions. A simple and rapid liquid chromatography in tandem with mass spectrometry (LC/MS-MS) with solid phase extraction (SPE) and isotope-labelled internal standard (IS) method was developed to monitor the plasma levels of OME for application in pharmacokinetics and drug-drug interactions studies. OME and its IS (OME-D3), were eluted with Zorbax extend C-18 rapid resolution (4.6 mm x 50 mm, 3.5 μm) at 25ºC, under isocratic conditions through a mobile phase consisting of 1 mM ammonium acetate, pH 8.5 (55%), and acetonitrile (ACN, 45%). The flow rate was 0.8 mL/min and the run time of chromatogram was 1.2 min. OME was detected and quantified by LC-MS/MS with positive electrospray ionization (ESI) that operates in multiple-reaction monitoring (MRM) mode. The method was linear in the range of 1.5-2000 ng/mL for OME. The validation assays of accuracy and precision, matrix effect, extraction recovery and stability of the samples for OME did not deviate more than 20% for the lower limit of quantification (LLOQ) and no more than 15% for other quality controls (QCs), according to regulatory agencies. 
Introduction
The prodrug omeprazole (OME) is a substituted benzimidazole (6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-benzimidazole) that acts as a specific PPI by reducing the amount of gastric acid produced by parietal cells. OME was the first PPI used to treat stomach ulcers, gastroesophageal reflux disease, Zollinger-Ellison syndrome, and infection by Helicobacter pylori [1] [2] [3] . The bioavailability after a single oral dose of 40 mg OME is approximately 58% owing to first-pass liver metabolism [1] [2] [3] Drug-drug interactions with OME result from increased gastric pH or inhibition of the metabolism of some drugs 4, 5 . For instance, phenytoin, warfarin, diazepam, and citalopram decreased clearance [6] [7] [8] [9] ; digoxin increased and clopidogrel decreased absorption 10, 11 . Therefore, the extensive pharmacokinetic variability of OME and its interactions with other drugs-few are clinically significant-mean that there are situations in which OME must be monitored. Dosage would therefore have to be tailored to individual patient requirements, and pharmacokinetic studies would be necessary to clarify drug-drug interactions, particularly in the case of polymedicated elderly patients or those receiving drugs with a narrow therapeutic index.
To date, plasma OME levels have been analyzed using high-performance liquid chromatography (HPLC) with coulometric detection 12 and ultraviolet detection (UV)
by enhancement from the sample matrix 26 and interference from metabolites 27 . Solid phase extraction (SPE) and application of an isotope-labeled internal standard (IS) reduced the matrix effect. Matuszewski 28 showed that the use of stable isotope-labelled IS eliminated the relative matrix effect due to similarities between physical-chemical properties, thus reducing variability during sample preparation and ionization.
However, most LC-MS/MS methods with ESI are based on protein precipitation (PPT) 22 Therefore, the aim of the present study was to develop a simple, sensitive, and reproducible LC-MS/MS method based on SPE and isotope-labelled IS (OME-D3) to monitor plasma levels of OME in pharmacokinetics and drug-drug interaction studies using enhanced speed of analysis and optimized chromatographic conditions.
Materials and Methods

Chemicals and reagents
All chemicals were analytical or LC-MS grade. OME (6- 
Stock solutions, calibration standards (CALs), and quality controls (QCs)
Two separate stock solutions of OME, one for CALs and another for QCs were prepared by dissolving an accurately weighed quantity in MeOH to obtain a concentration of 1 mg/mL. Both stock solutions were diluted independently to obtain several secondary and working solutions for the preparation of CALs and QCs. The IS (OME-D3) stock solution was prepared by dissolving an exact amount in MeOH to obtain a concentration of 1 mg/mL and diluted 40 times to give a working solution of 25 μg/mL. CALs were prepared by independent dilution, in which a specific volume of secondary CAL solutions (0.15 g/mL, 1 mg/mL, 5 g/mL, 20 g/mL, 50 g/mL, 100 g/mL, 150 g/mL, and 200 g/mL) was added to blank plasma to obtain concentrations of 1.5, 10, 50, 200, 500, 1000, 1500, and 2000 ng/mL, respectively. A calibration curve (1.5 to 2000 ng/mL) was thus generated according to the recommendations of the United States Food and Drug Administration (FDA) 30 and the European Medicines Agency (EMA) 31 for bioanalytical method validation. QC samples were also made by independent dilution, in which a specific volume of QC secondary solutions (0.15 g/mL, 0.45 g/mL, 900 g/mL, and 1600 g/mL, respectively) was added to blank plasma to obtain concentrations of 1.5 ng/mL (LLOQ), 4.5 (QC Low ), 900 ng/mL (QC Medium ), and 1600 ng/mL (QC High ), respectively. A drug-free blank plasma sample and drug-free zero plasma sample (processed with IS) were included. All CAL and QC solutions were stored at -80°C until analysis to avoid more than 3 cycles of freezing. Storage was no longer than 2 months.
Chromatographic conditions
The HPLC system consisted of a 1200 Series separation module (Agilent Technologies, It is important to maintain this pH during recording, because OME is very sensitive to acidic pH. The chromatographic run was performed under isocratic conditions at a flow rate of 0.8 mL/min with 55% solution A and 45% solution B. The elution time of each sample was 0.889 min for OME and 0.884 min for OME D3. The total run time was 1.2 min, and a re-equilibration time was not required owing to the isocratic conditions used. At the end of every day, the column was washed by increasing the percentage of ACN to 100% at a 0.8-mL/min flow rate for 20 min and then returning to the initial conditions within 5 min. Washing was then continued for a further 10 min.
Mass spectrometry
The mass spectrometry detection system consisted of an Agilent Technologies 6410 triple quadrupole mass spectrometer with ESI in positive ion mode. Mass spectrometry was performed in multiple-reaction monitoring (MRM) mode. Desolvation gas (N 2 ) and flow were set at 310°C and 8.5 L/min, respectively. Thus, the acetic acid of the mobile phase was easily volatilized at this temperature. The nebulizer pressure was 40 psi, which assured good nebulization efficiency for the chromatographic conditions; the capillary voltage was 4 kV. The mass spectrometry collision gas was high-purity N 2 (> 99.9995). The fragmentor voltage was 75 V and dwell time 200 ms for all compounds.
The collision energy was set at 5 eV for OME (quantifier ion) and OME-D3, and at 15 eV for OME (qualifier ion). After separation with HPLC, the peak area corresponding to the transition m/z 346.2 → 198.1 for OME (quantifier ion) was measured relative to that of the transition m/z 349.2 → 198 for its IS (OME-D3). For identification of OME, the m/z 346.2 → 151.1 reaction for the qualifier ion was also monitored to add specificity (Supplementary Table 1 and Fig. 1A-B) . The integration peak area of the MRM transitions of each analyte was calculated using MassHunter Workstation
Quantitative Analysis software (Agilent Technologies, Madrid, Spain).
Sample preparation
Samples were prepared by SPE using Nexus Versaplate Bond Elute C18 and 30 mg of polymeric sorbent (Agilent Technologies, Madrid, Spain) with a vacuum pressure of about 3-5 mmHg. The sample was applied after pre-conditioning of the cartridges with 1000 L MeOH followed by 1000 L Milli-Q water. This procedure was carried out by spiking 200 L of plasma with 10 L of IS (25 g/mL) and 790 L of ammonium acetate 1 mM (pH 8.5) for one sample, although the IS was calculated for more samples and pre-mixed with ammonium acetate for the general procedure. Next, a washing step was performed with 1000 L of 95% ammonium acetate 1 mM (pH 8.5) in 5% MeOH.
Elution was performed with 1000 L of 90% MeOH and 10% ACN plus 1% ammonium acetate 1 mM in water (pH 8.5), which was collected on a 96-well (1 mL) plate. After extraction, samples were transferred to vials or they were directly read from the collection plate. Only 1 L of eluate was directly injected into the LC-MS/MS. The whole sample preparation procedure was carried out at pH 8.5 to ensure the stability of OME, which degrades rapidly under acidic solutions 32 .
Assay validation procedures
The method was validated in order to demonstrate the reliability of OME in plasma, its biological matrix. Accordingly, the authors followed the recommendations published online by the FDA 30 and the EMA 31 .
Calibration curve and LLOQ
Quantitative analysis of OME in plasma was performed using OME D3 as the IS. Eight calibration standards-1.5, 10, 50, 200, 500, 1000, 1500, 2000 ng/mL-were used for validation. A weighted least-square linear regression model was used to calculate the equation relating the ratio of the area of OME to the area of IS and the concentration of OME in the calibration standards. The inverse of the concentration (1/X 2 ) was used as a weighting factor. Six standard curves were analyzed. The standard curve was chosen to cover the range of clinically relevant concentrations expected in most patients. To validate the curve, at least 6 of 8 calibration standards should be less than 15% of the coefficient of variation (CV). For each point of the calibration curve, the error of accuracy and CV should be less than 15% for all calibration standards, except for the LLOQ, which was less than 20%. The LLOQ response of the analyte should be at least 5 times higher than the blank response.
Precision and accuracy
The precision, repeatability, and accuracy of the assay (ie, the closeness of the determined value to the true value) are critical factors when measuring reproducibility. Precision is defined as a coefficient of variation (%). Accuracy was measured as the percentage difference between the theoretical and the measured value according to the following equation:
To verify precision and accuracy, error must be less than 15% for all samples except the LLOQ (<20%).
Selectivity
The selectivity of the method was examined by analyzing 6 different lots from human blank plasma, with the IS (zero plasma) or without the IS. Each blank or zero sample was tested for interference. The method is considered selective when the response is less than 5 times the LLOQ for OME and less than 20 times for the IS.
Extraction recovery and matrix effect
Recovery is measured as the ratio of the compound concentrations in plasma following SPE to the same concentration dissolved directly in elution solution. The matrix effect of plasma was investigated by addition of a known concentration of analyte with its IS to a human blank plasma sample that had undergone SPE. The response was compared with the addition of the same amount of analyte and IS to the final elution solution. This time, 6 repetitions per concentration were analyzed in 6 different lots of human plasma at 4.5 ng/mL (QC Low ) and 1600 ng/mL (QC High ) for OME. To validate the matrix effect, the coefficient of variation (CV) could not be larger than 15% for all the QCs.
Stability
For OME to guarantee the storage conditions and each step taken during sample preparation and analysis, the authors conducted the following stability assays at 4.5 ng/mL (QC Low ) and 1600 ng/mL (QC High ):
-after 3 cycles of freeze-thaw in the freezer at -80ºC -after 24 h at room temperature (short-term stability)
-after 7 h at 23°C in the autosampler -after 72 h at 4ºC in the fridge -after 2 months at -80ºC in the freezer (long-term stability)
For all studies, 3 replicates of QC Low and QC High for OME were performed and analyzed according to requirements. Analyte stability had to be less than 15% for all the QCs used.
Carry-over
During validation, carry-over was assessed by injecting blank samples after a high concentration sample or CAL at the upper limit of quantification (2000 ng/mL). Carryover in the blank sample following the high concentration standard could not be greater than 20% of the LLOQ. The needle was washed between injections with water (55%) and ACN solution (45%) to prevent carry-over.
Preliminary human experiments
The proposed method was applied to determine the plasma profile of OME after a standard oral dose (40 mg single dose) of OME (Losec 
Results
Optimization of MS/MS conditions and chromatography
The ESI in positive mode and full scan spectra of all compounds indicated that the most abundant ions were the protonated molecules ([MH] + ), which were therefore selected to detect the most abundant products. The percent abundance of the precursor and product ions of the quantifier, qualifier, or IS versus mass to charge (m/z) are shown in Fig. 1A -B under product ion mode. The fragmentation patterns are also shown. Optimized mass spectrometer parameters such as scan time, fragmentor voltage, and collision energy for OME (quantifier and qualifier ion) and for its IS in MRM mode are summarized in Supplementary Table 1 .
Fig. 1C shows a typical extraction ion chromatogram (EIC) of plasma spiked
with QC Medium (900 ng/mL) and its IS (1190 ng/mL) in MRM mode. The areas and retention times (RT) are shown. Although the RT of OME (0.889 min) and its IS (0.884 min) are very close, they can be separated by the analysis of EIC based on reconstructed ion currents. In addition, total recording time was too short (1.2 min) and did not require a post-time for re-equilibration owing to isocratic elution.
Calibration curve and LLOQ
The calibration curves with the 8 CALs of OME were linear in the range from 1.5 ng/mL to 2000 ng/mL, with lines of regression forced through the origin. The slope and correlation coefficient (r 2 ) values were 0.1152 ± 0.0039 and 0.9967 ± 0.0014, respectively, for the average of 6 calibration curves.
The LLOQ at 1.5 ng/mL (Fig. 2) showed an identifiable and reproducible response with an intra-day accuracy of 4.3% and CV of 2.7% and inter-day accuracy of 13.0% and CV of 8.7% (Table 2 ). The response was more than 5 times higher than that of any target plasma (364 ± 16.65 signal/blank signal). In all CALs, the accuracy did not exceed ±15% of the theoretical value, including the LLOQ. Supplementary Fig. 1A shows a representative total ion chromatogram (TIC) of a blank plasma sample without IS. Supplementary Fig. 1B and 1C display a typical EIC of blank plasma with IS (zero plasma) and plasma spiked with 1.5 ng/mL (LLOQ) of OME, respectively. The area values of LLOQ of OME (523) are higher than those found for this compound in a human blank plasma sample, taking into account that all chromatograms were normalized to the largest peak.
Precision and accuracy
The precision and accuracy of the method were assessed by analyzing replicates of 5 samples of 1.5 ng/mL (LLOQ), 4.5 ng/mL (QC Low ), 900 ng/mL (QC Medium ), and 1600 ng/mL (QC High ) for OME. The standard deviation (SD), CV, and accuracy were calculated for each sample. Table 1 summarizes the results for precision and accuracy of the validation method. The intra-day precision was optimal, with CVs of between 1%
and 6%, and accuracy was optimal between 4% and 8%. Variations in inter-day precision were less than 15%, even for the LLOQ (1.5 ng/mL), with CVs of between 5% and 13% and accuracy of between 7% and 13%. We can conclude that the method is reproducible and accurate for OME.
Selectivity
The present method was selective, as no interference was found in the detection of OME in the absence or presence of IS in 6 different blank samples. Supplementary   Fig. 1 shows the lack of interference of a representative total ion chromatogram (TIC) of blank plasma samples with IS ( Supplementary Fig. 1A ) or without IS (Supplementary Fig. 1B) . The area of the zero plasma with IS is much more than 20 times the area of the blank plasma of OME (209,901 ± 16,589). Similarly, the EIC showed no interference at the LLOQ of OME (Supplementary Fig. 1C ).
Extraction recovery and matrix effect
The extraction recovery of human plasma was determined at 4.5 ng/mL (QC Low ), 900 ng/mL (QC Medium ), and 1600 ng/mL (QC High ) of OME compared with the blank plasma samples spiked with a known concentration of OME after SPE and immediately before injection. The mean recoveries were 103.8%, 87.0%, and 85.9%, and the CVs were in the range of 3% to 12% at the 3 given concentrations, respectively. Therefore, the extraction recoveries were higher than 86% and the bias less than 12%; the extraction was accurate and reproducible, as the recommendations suggest ( Table 2 ).
The matrix effect was carried out at 4.5 ng/mL (QC Low ) and 1600 ng/mL (QC High ) in 6 different human plasma samples. The mean matrix effect (relative extraction) was more than 94%, and the CVs were in the range of 6% to 8%. No matrix effect was observed after the tests were performed; consequently, the response of OME was not significantly reduced by ion suppression ( Table 2 ).
Stability
The stability assays at 4.5 ng/mL (QC Low ) and 1600 ng/mL (QC High ) of OME are summarized in Table 2 . Stability tests after 3 freeze-thaw cycles in the freezer at -80ºC
showed no degradation, with a mean of more than 95% and CV in the range of 2% to 4%. The short-term stability test after 24 h at room temperature revealed a mean of more than 99% and CV in the range of 4% to 5%. After 7 h at 23ºC in the autosampler, the stability test revealed a mean of more than 98% and CV in the range of 1% to 6%.
The stability test after 72 h at 4ºC in the fridge also showed a mean of more than 98%
and CV in the range of 1 to 2. Moreover, the extracts were stable after 2 months at -80ºC (long-term), with a mean of more than 93% and CV in the range of 3% to 8%. The CV was less than 9% in all cases, and the mean was close to 100%.
Carry-over
The carry-over in the blank sample following the high-concentration standard calibration was 7.2 ± 4.76% of the LLOQ, i.e., less than 20%. Thus, in line with EMA regulations, OME did not present carry-over 31 .
Application of the method
The method the authors developed was successfully applied to pharmacokinetic analysis of 240 samples from 6 healthy volunteers who received an oral dose of OME (Losec ® , 40 mg). Fig. 2 shows OME plasma concentration versus time acquired after administration of OME (0 h to 12 h) in the 6 healthy volunteers. The average maximum plasma concentration (C max ) was 1,395.18 ± 814.67 ng/mL at 1.61 (1.00-3.00) h (T max )
after administration of OME. Table 3 shows the mean pharmacokinetic parameters of OME after oral administration of 40 mg of OME under fasting conditions. All the results were within the range of 1.5-2000 ng/mL in the calibration curves. "Our approach was similar to that of clinical practice, since 3 of the 6 healthy volunteers were taking concomitant therapy: norgestimate-ethinyl estradiol) 1 tablet/24 h, acetaminophen 1 g, and ibuprofen 600 mg. Even though these very common over-the-counter drugs were taken by our patients, the selectivity of our assay remained unaltered. No interference was observed with any of them during the study".
Discussion
PPIs are among the most consumed over-the-counter drugs. OME is widely used and has marked inter-subject variability owing to the different activities of the cytochrome P 450 system 1, 22, 33 . Drug monitoring should take account of broad pharmacokinetic variability, which makes the relationship between dose and plasma concentration and therapeutic effect unpredictable. Administration of OME can become problematic because of drug-drug interactions, which are especially relevant in patients with chronic diseases and those taking multiple drugs concomitantly or drugs with a narrow therapeutic index 2, 5 . Therefore, we developed an LC-MS/MS-based analytical method with SPE and isotope-labelled IS (OME-D3) to determine OME in human plasma, unravel new drug-drug interactions for pharmacokinetic studies, and thus improve clinical practice.
"The method was linear within a wide range of concentrations (1.5 to 2000 ng/mL), which facilitated measurement of the high inter-subject variability between samples". The LC-MS/MS the authors used had an LLOQ of 1.5 ng/mL for OME and higher sensitivity and selectivity than authors who used HPLC with UV detection between 3-96 ng/mL [13] [14] [15] [16] [17] [18] [19] . The most relevant LC-MS/MS-based methods have sensitivities of 0.05 ng/mL 23, 24 , 0.4 ng/mL 21 , and 1.2 ng/mL 22 , which were slightly lower than those used by the authors of the present study. In all of these studies, the run times were longer, and samples were prepared using LLE or PPT. Even in SPE, which better eliminates the interference of the matrix effect, the run times were too long 25, 29 .
Dodgen and coworkers 20 recorded short run times, although they used automated online SPE, which is only available in selected laboratories and difficult to obtain for routine application in hospitals.
Our chromatographic run lasted 1.2 min, which is shorter than times recorded elsewhere (>1.3 min 13, 15, 17, [21] [22] [23] [24] or even >16 min 17 ). The authors used a Zorbax Extend C-18 high-resolution column, which enabled us to work with a high flow of 0.8 mL min and provided a short analysis time.
The mass spectrometer was operated with the ESI source, which can produce matrix effects that alter ionization efficiency owing to the presence of co-eluting substances such as phospholipids, mobile phase modifiers, and formulation agents 34, 35 . "One of the advantages was the use of isotope-labeled IS and a more selective sample preparation procedure such as SPE, which helps to eliminate the matrix effect and improves assay selectivity 28 , as in the present study". The authors' approach achieved good recoveries, with average values of 86% to 104%, which are similar to those reported by Dodgen and coworkers 20 and Macek and coworkers 22 or better than those reported elsewhere (>63% 23 , 71% to 74% 24 , and 83% to 87% 17 ). These recoveries were achieved thanks to an ultraclean polymeric sorbent of SPE, which has bimodal porosity and a high surface area. Both the mobile phase and the whole sample preparation procedure were conducted using basic solutions (pH 8.5) so as not to degrade OME, as reported elsewhere 32 . The ratio of MeOH/ammonium acetate buffer at the washing step was critical to extraction yield, as reported by Martens-Lobenhoffer and coworkers 36 . The authors obtained the best result with 5% MeOH and 95% ammonium acetate, since a higher percentage of MeOH led to a loss of analyte. Other pH values (e.g., 9.5) during sample preparation, or decreasing percentages of ammonium acetate (e.g., 0.5 or 0.1) at the elution step did not increase the efficacy of recovery. "Another advantage of this procedure was that it did not require evaporation and subsequent reconstitution". The authors also studied the effect of carry-over, which is not investigated by most authors, and recorded a value of 7.2%, which is lower than that allowed by the EMA 31 , thus showing the quality of the method presented here.
We also used small injection volumes (1 L) to minimize interference and matrix effect, since desorption is easier to perform. The method used only 200 L of plasma, which is less than that reported elsewhere (250 to 450 L [21] [22] [23] [24] or even 1000 L 17 ). Hence, the quantity of plasma required to validate the bioanalytical methods is reduced.
Finally, this procedure was successfully applied in the analysis of 240 samples from 6 healthy volunteers with a mean (± SD) C max of 1395.18 ± 814.67 ng/mL. The mean plasma concentration was higher under fasting conditions than with food 37 . These results are in line with those of previous reports on the pharmacokinetics of OME by Liu and coworkers (C max of 1330.46 ± 758.07 ng/mL) 38 . Other authors reported lower C max owing to lower doses of OME 24, 39 . The high inter-subject variability indicated by the error bars in Fig 2 is similar to the findings reported by other authors 22, 38 , thus making them suitable for monitoring. and area values are given for OME and OME-D3. These values were calculated from the EIC. All chromatograms have been normalized to the largest peak. Table 1 . Intra-day and inter-day precision and accuracy. Data were obtained from 4 quality controls (QCs) of omeprazole (OME; 1.5, 4.50, 900, and 1600 ng/mL) repeated 5 times on the same day for precision and accuracy intra-day and on 3 consecutive days for inter-day assays. The lower limit of quantification (LLOQ) was 1.5 ng/mL. The mean ± SD of the number of total experiments is shown in parenthesis. . EIC of plasma spiked with the lower limit of quantification (LLOQ) at 1.5 ng/mL of omeprazole (OME, C). Retention times (RT) and height and area values are given for OME and IS.
Conclusion
All chromatograms have been normalized to the largest peak.
Supplementary Table 1 . Ions and fragmentation conditions used for multiple reaction monitoring (MRM) for omeprazole (OME) and its internal standard (IS), OME-D3. 
